Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Joost Lesterhuis

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Molecular Immunology|October 18, 2011
PD-L2 is predominantly expressed by Th2 cellsW Joost Lesterhuis, Henry Steer, Richard A Lake
Science Translational Medicine|March 28, 2014
Comment on "drug discovery: turning the titanic"W Joost Lesterhuis, Anthony Bosco, Richard A Lake
Oncoimmunology|June 22, 2012
STATing the importance of immune modulation by platinum chemotherapeuticsStanleyson V Hato, I Jolanda M de Vries, W Joost Lesterhuis
Current Opinion in Immunology|January 3, 2016
Chemotherapy and immunotherapy: mapping the road aheadAlistair M Cook, W Joost Lesterhuis, Anna K Nowak, et al.
Nature Reviews. Drug Discovery|August 2, 2011
Cancer immunotherapy--revisitedW Joost Lesterhuis, John B A G Haanen, Cornelis J A Punt
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2014
Molecular pathways: the immunogenic effects of platinum-based chemotherapeuticsStanleyson V Hato, Andrea Khong, I Jolanda M de Vries, et al.
Journal of Medicinal Chemistry|November 11, 2025
A New Era for PPARγ: Covalent Ligands and Therapeutic ApplicationsJasmine L King, Luke Smithers, Alice Vrielink, et al.
Clinical & Developmental Immunology|May 22, 2012
Programmed death ligand 2 in cancer-induced immune suppressionEsdy N Rozali, Stanleyson V Hato, Bruce W Robinson, et al.
Nature Medicine|May 4, 2004
Dendritic cell immunotherapy: mapping the wayCarl G Figdor, I Jolanda M de Vries, W Joost Lesterhuis, et al.
Journal of Visualized Experiments : Jove|August 18, 2020
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant TherapiesFrancois X Rwandamuriye, Breana J Weston, Terrance G Johns, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Molecular Immunology|October 18, 2011
PD-L2 is predominantly expressed by Th2 cellsW Joost Lesterhuis, Henry Steer, Richard A Lake
Science Translational Medicine|March 28, 2014
Comment on "drug discovery: turning the titanic"W Joost Lesterhuis, Anthony Bosco, Richard A Lake
Oncoimmunology|June 22, 2012
STATing the importance of immune modulation by platinum chemotherapeuticsStanleyson V Hato, I Jolanda M de Vries, W Joost Lesterhuis
Current Opinion in Immunology|January 3, 2016
Chemotherapy and immunotherapy: mapping the road aheadAlistair M Cook, W Joost Lesterhuis, Anna K Nowak, et al.
Nature Reviews. Drug Discovery|August 2, 2011
Cancer immunotherapy--revisitedW Joost Lesterhuis, John B A G Haanen, Cornelis J A Punt
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2014
Molecular pathways: the immunogenic effects of platinum-based chemotherapeuticsStanleyson V Hato, Andrea Khong, I Jolanda M de Vries, et al.
Journal of Medicinal Chemistry|November 11, 2025
A New Era for PPARγ: Covalent Ligands and Therapeutic ApplicationsJasmine L King, Luke Smithers, Alice Vrielink, et al.
Clinical & Developmental Immunology|May 22, 2012
Programmed death ligand 2 in cancer-induced immune suppressionEsdy N Rozali, Stanleyson V Hato, Bruce W Robinson, et al.
Nature Medicine|May 4, 2004
Dendritic cell immunotherapy: mapping the wayCarl G Figdor, I Jolanda M de Vries, W Joost Lesterhuis, et al.
Journal of Visualized Experiments : Jove|August 18, 2020
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant TherapiesFrancois X Rwandamuriye, Breana J Weston, Terrance G Johns, et al.
Pageof 6